Abstract:Abstract Krüppel-like factor 5 (KLF5) is an evolutionarily conserved zinc finger-containing transcription factor promoting breast cell proliferation, survival, and tumor growth through upregulating its target gene FGF-BP. The protein abundance of KLF5 has been shown to be strictly regulated at transcriptional and posttranslational levels. Our previous studies suggest that the KLF5 protein degradation is through the ubiquitin proteasome pathway. The WWP1 E3 ligase can target KLF5 for ubiquitin-mediated proteasomal degradation. In this study, we demonstrated the F-box protein FBW7 targets KLF5 for proteolysis and suppresses KLF5's functions in breast cancer. The SCFFBW7 (SKP1-Cullin1-F-box) E3 ligase complex has been shown to target several oncoproteins, including MYC and CyclinE, for proteolysis. FBW7 could be a tumor suppressor due to its frequent mutations in multiple cancers. Here, we first demonstrated that inactivation of endogenous FBW7 by gene knockout, knockdown, or mutation remarkably increases the endogenous KLF5 protein abundances through blocking its degradation in multiple cell lines. Second, we found that overexpression of FBW7 decreases the exogenous and endogenous KLF5 protein levels in HEK293T and SUM149PT cell lines. Functionally, overexpression of FBW7 in the endogenous FBW7 mutated SUM149PT cells decreases the FGF-BP gene expression and the DNA synthesis. Importantly, knockdown of endogenous Fbw7 increases the FGF-BP gene expression, cell proliferation, and survival through upregulating the KLF5 expression in breast cells. These findings suggest that the Fbw7 tumor suppressor inhibit breast cancer cell proliferation and survival at least partially through targeting KLF5 for ubiquitin-mediated degradation. This new regulatory mechanism of KLF5 degradation may result in useful diagnostic and therapeutic targets for breast cancer and other cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3155.

The Fbw7 Tumor Suppressor Regulates Glycogen Synthase Kinase 3 Phosphorylation-Dependent C-Myc Protein Degradation

Global and context-specific transcriptional consequences of oncogenic Fbw7 mutations

The Fbw7 Tumor Suppressor Targets Klf5 For Ubiquitin-Mediated Degradation And Suppresses Breast Cell Proliferation

Regulation of APC Cdh1 E3 Ligase Activity by the Fbw7/cyclin E Signaling Axis Contributes to the Tumor Suppressor Function of Fbw7

Functional Characterization of FBXL7 As a Novel Player in Human Cancers

Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation

Ubiquitylation of unphosphorylated c-myc by novel E3 ligase SCFFbxl8

CRL2 KLHDC3 and CRL1 Fbxw7 cooperatively mediate c-Myc degradation

Tumor suppressor bromodomain-containing protein 7 cooperates with Smads to promote transforming growth factor-β responses

A germline point mutation in the MYC-FBW7 phosphodegron initiates hematopoietic malignancies

ERK Kinase Phosphorylates and Destabilizes the Tumor Suppressor FBW7 in Pancreatic Cancer.

Abstract 3155: the SCFFBW7 E3 Ubiquitin Ligase Targets Krüppel-like Factor 5 (KLF5) for Proteolysis in Breast Cancer

Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase

FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2

The Scffbw7 E3 Ubiquitin Ligase Complex Targets Klf5 For Ubiquitination And Degradation In A Phosphorylation Dependent Manner

Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3

Function and regulation of F-box/WD repeat-containing protein 7

Tumor Suppressor FBXW7 and Its Regulation of DNA Damage Response and Repair

FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation

Clinical significance of FBXW7 loss of function in human cancers

FBXL6 degrades phosphorylated p53 to promote tumor growth